sever earli phase clinic trial rais enthusiasm insulinlike growth factor receptor igfrspecif antibodi cancer treatment initi phase iii result unselect patient disappoint 
clinic studi mai benefit predict biomark identifi probabl respond ration combin therapi altern target strategi ligandspecif antibodi receptorspecif tyrosin kinas inhibitor 
target insulin igf signal consid broader context pathophysiolog relat obes diabet neoplasia effect antidiabet drug includ metformin cancer risk prognosi 
insulin igfi receptor famili relev develop pikakt pathwai inhibitor 
